Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nanoscribe is a German advanced-manufacturing company that develops and sells high-resolution 3D microfabrication systems, materials, software, and related services based on Two-Photon Polymerization. The company serves research and industrial customers across photonics, micro-optics, micromechanics, microfluidics, and selected life-science applications such as tissue engineering and biomedical research. Its flagship commercial product family includes the Quantum X systems, including Quantum X bio for high-resolution 3D biofabrication. Nanoscribe is not a drug developer; rather, it is a tools and platform company whose products enable fabrication of micro- and nanoscale structures for life science and healthcare research as well as non-healthcare markets. The company was founded as a spin-off from the Karlsruhe Institute of Technology and is now part of LAB14 Group after previously being owned by BICO.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nanoscribe.